News | January 11, 2026
PAI Pharma acquires Nivagen to boost US injectable drug production
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Subscribe To Our Newsletter & Stay Updated
